Indications for Heart Transplantation in Congenital Heart Disease by Siân Pincott, E & Burch, M
  Current Cardiology Reviews, 2011, 7, 51-58  51 
     1573-403X/11 $58.00+.00  © 2011 Bentham Science Publishers 
Indications for Heart Transplantation in Congenital Heart Disease 
E. Siân Pincott* and M. Burch 
Department of Cardiology, Great Ormond Street Hospital, Great Ormond Street, London WCIN 3JH 
Abstract: In this review we have looked at indications for cardiac transplantation in congenital heart disease. An outline 
of the general principles of the use of transplant as a management strategy both as a first line treatment and following 
other surgical interventions is discussed. We explore the importance of the timing of patient referral and the evaluations 
undertaken, and how the results of these may vary between patients with congenital heart disease and patients with other 
causes of end-stage heart failure. The potential complications associated with patients with congenital heart disease need 
to be both anticipated and managed appropriately by an experienced team. Timing of transplantation in congenital heart 
disease is difficult to standardize as the group of patients is heterogeneous. We discuss the role and limitations of investi-
gations such as BNP, 6 minute walk, metabolic exercise testing and self estimated physical functioning. We also discuss 
the suitability for listing. It is clear that congenital heart patients should not be considered to be at uniform high risk of 
death at transplant. Morbidity varies greatly in the congenital patient population with the failing Fontan circulation having 
a far higher risk than a failing Mustard circulation. However the underlying issue of imbalance between donor organ sup-
ply and demand needs to be addressed as transplant teams are finding themselves in the increasingly difficult situation of 
supporting growing numbers of patients with a diverse range of pathologies with declining numbers of donor organs.  
Keywords: Congenital heart disease (CHD), heart transplantation, paediatric. 
BACKGROUND 
  The surgical technique of cardiac transplantation was 
first described in 1960, followed seven years later by the first 
successful human heart transplant. The procedure has subse-
quently evolved to provide a hugely important treatment 
modality to manage cardiac conditions which have either 
exhausted medical management strategies or would other-
wise prove terminal. Although transplant is a valuable treat-
ment, with the benefits of improving quality and duration of 
life, it is does not offer a cure in the conventional sense as it 
is currently unable to restore a fully normal life expectancy. 
The use of transplant is restricted by rigorous selection crite-
ria of the transplant programme, assessment of the presenting 
condition, underlying pathology and co-morbidities being 
essential for full evaluation of the patient as to their suitabil-
ity for transplant. The programme is limited however by the 
availability of donor organs, resulting in an increasing mis-
match between supply and demand within the transplant 
service. As a result even with stringent assessment of those 
deemed suitable for transplant, additional consideration must 
be made to finding the most suitable recipient for the scarce 
and precious donor organ when it does become available.  
  Conditions for which transplant may be an option are 
similar in both adult and paediatric populations, however the 
proportions of each presenting condition understandably are 
very different. In general heart transplantation is considered 
in individuals with end stage heart failure, with a life expec-
tancy of less than 18 months, where other medical therapy 
has been exhausted or ineffective. Heart transplant is 
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generally offered to patients who are under the age of 60 
years. There are absolute and relative contraindications to 
cardiac transplantation, including significant medical, infec-
tive and psychiatric co-morbidities in addition to physiologi-
cal status at the time of assessment, however there are no UK 
or international guidelines specifically relating to patients 
with congenital heart disease (See Appendix A). In children 
with congenital heart disease the general indications for 
transplant are the same as for other patient groups described 
above. More specific situations where cardiac transplant is 
appropriate include pulmonary atresia with intact septum, 
heterotaxy syndromes with
  anomalous pulmonary venous 
return and severe valve disease [1]. 
  Approximately 1 in every 145 births in the UK is af-
fected by congenital heart conditions [2] some are antena-
tally diagnosed but the majority are not detected until after 
delivery. The congenital defects arising may be minor, re-
quiring no or minimal intervention, others are more severe 
and need graded management, either medical or surgical. 
With improving diagnostic, neonatal, intensive care and sur-
gical skills increasing numbers of children with more severe 
lesions are able to survive childhood and into adult life.  
  Of the 4,600 babies born with congenital heart disease 
every year in the UK [3] approximately 800 undergo surgical 
procedures in the neonatal period, 1500 within the first year 
and a further 1500 within the first 16 years of life [4]. These 
procedures may be reparative, staged or palliative depending 
on the underlying diagnosis and are associated with varying 
consequent degrees of morbidity and mortality.  
  In the UK during the period 2009 to 2010 120 heart 
transplants were performed, of which 40 were in children 
(heart-lung transplant data for the same period being 5 in 
adults and none in children) [5]. Worldwide of the infants 
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disease whereas over one year of age this proportion reduced 
to only a third [6]. In congenital heart disease heart trans-
plant may be offered as a primary management or offered 
after palliative or reparative surgical attempts either acutely 
or after a period of gradual failure. 
HEART TRANSPLANTATION IN PATIENTS WITH 
CONGENITAL HEART DISEASE 
  The majority of patients with congenital heart disease 
who receive a heart transplant do so after other surgical in-
terventions have been attempted, either palliative or repara-
tive. Those who receive a transplant as a first line manage-
ment usually do so in early life, with subsequent peaks of 
transplants occurring in the 6 month to 6 year age group, 
adolescents and 20-40 year age group, reflecting the natural 
course of the underlying pathologies [7]. Increasing numbers 
of patients with congenital heart defects are surviving as a 
result of improved surgical and medical techniques as well as 
intensive care services. This results however in a larger 
number of patients presenting outside the period of infancy 
with end stage heart failure, requiring transplantation. The 
expanding congenital patient group placing extra strain on 
this already stretched resource.  
THE USE OF HEART TRANSPLANTATION AS 
FIRST CHOICE TREATMENT 
  Heart transplants used as the first line management op-
tion for patients with congenital heart disease are usually 
performed in infancy. As a treatment modality it is deemed 
appropriate to offer the opportunity of transplant if the con-
genital lesion is not suitable for other surgical intervention or 
if the risk of other management, including surgery, is greater 
than that of transplant itself. On this basis transplant for pa-
tients with hypoplastic left hearts was advocated early in the 
history of paediatric cardiac transplantation when the out-
come of palliative procedures was less successful. The early 
positive results seen as a result of transplant in these patients 
demonstrated its possible utilisation in the management of 
other cardiac conditions requiring intervention in early life 
and resulted in its wider use in the management of other 
congenital cardiac lesions, disease and cardiomyopathies of 
infancy. The outcome of staged palliative surgical proce-
dures for hypoplastic left heart has subsequently improved 
and as a result the use of transplant as first line management 
in hypoplastic left heart disease has decreased [7].  
  The early experience of the newborns with hypoplastic 
left hearts has resulted in the wider use of transplant in in-
fancy for other pathologies. As a consequence the infant do-
nor pool has remained relatively constant. Congenital lesions 
that are now considered for heart transplant as a first choice 
management include hypoplastic left heart with abnormali-
ties which preclude the Norwood operation (eg impaired 
ventricular function), severe Ebstein’s anomaly, pulmonary 
atresia with intact ventricular septum associated with abnor-
mal coronary anatomy, severe valve abnormalities and het-
erotaxy lesions  
  Transplantation in infancy appears to confer an immu-
nological advantage long term, as infants do not produce 
ABO antibodies for the first few months of life and so their 
risk of hyper-acute rejection related to ABO incompatibility 
is reduced [8]. ABO mismatched transplants, usually contra-
indicated in older patients, can therefore be performed in this 
group increasing the potential donor pool. The age limit for 
such mismatched transplants is generally determined by 
measurement of circulating isohaemagglutinins in the indi-
vidual [9]. The risk of rejection related to HLA antibodies 
remains unchanged and is discussed later. 
  Post transplant coronary artery disease is also seen less in 
infants, possibly related to infection exposure of both the 
donor and recipient.  
THE USE OF HEART TRANSPLANTATION AFTER 
ONE OR MORE SURGICAL PALLIATIONS 
  Heart transplantation may be required after previous car-
diac surgical procedures, many operations performed for 
patients with congenital heart disease not being curative, and 
ultimately resulting in heart failure after variable periods of 
time. A patient may be referred for transplant acutely if peri-
operative complications are encountered, or electively after a 
longer period of management following a corrective or pal-
liative procedure.  
  Surgery performed on patients with congenital heart con-
ditions may be complicated by associated defects such as 
abnormal situs, presence of collaterals and atypical vascula-
ture. Unusual anatomy makes accurate transplant assessment 
of this patient group more difficult. Pulmonary vascular re-
sistance (PVR) needs to be assessed prior to transplant to 
avoid later post transplant right heart failure in the trans-
planted heart [10]. PVR measurement is used as an indica-
tion of feasibility of transplant, high fixed PVR a contraindi-
cation to orthotopic heart transplant, although heterotopic or 
heart-lung transplants may still be an option. 
  In some cases the PVR is elevated post Fontan proce-
dure. The failing Fontan is a difficult situation where collat-
erals and intracardiac shunts make accurate estimation of the 
PVR complicated. Fontan circulation deterioration may pre-
sent as either ventricular failure with a normal PVR or with 
high venous pressures and relatively preserved cardiac func-
tion, the latter is usually related to high PVR. Failing Fontan 
physiology may be demonstrated clinically by protein losing 
enteropathy, ascites, plastic bronchitis and pleural effusions 
[11]. The consequences of this abnormal physiology are sig-
nificant and elevate the mortality risk in patients who subse-
quently receive a transplant, the high PVR increasing the 
probability of right heart failure post transplant. Transplant 
for the single ventricle appears to be at much lower risk if 
undertaken at the stage of systemic or venous shunt rather 
than completed Fontan [12].  
REFERRAL FOR ASSESSMENT BY A TRANSPLANT 
TEAM 
  Early transplant assessment of any patient but particu-
larly those with congenital heart disorders is clearly prudent 
[13]. Assessment provides an opportunity to evaluate the 
patient and institute management measures to reduce the 
impact of co-morbidities or interventions which may later 
limit their consideration for heart transplantation. Alterna-
tively, after evaluation when non-transplant based options 
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measures can be discussed and instituted early as short or 
long term care strategies. 
ASSESSMENT 
  The transplant assessment is a dynamic process involving 
physiological and psychological determination of parameters 
regarding the potential recipient which may indicate short 
and long term, pre, peri and post operative complications for 
consideration.  
HISTORY 
  A full previous medical history must be taken from the 
patient and allied professionals and medical records provid-
ing details of previous surgical interventions or cardiotho-
racic procedures that may help evaluate the previous anat-
omy and condition of the recipient. Surgical procedures con-
fer different risks for any subsequent transplant to the indi-
vidual patient through sensitisation, increased risk of bleed-
ing, infection, wound dehiscence and adhesions. Previous 
surgery may have implications of later complications at 
transplant surgery. Repeat sternotomies may increase the risk 
of re-entry injury however data seems to suggest that this is 
not associated with increased risk of subsequent morbidity or 
of peri-operative mortality, it should however remain a factor 
for the operating team to be aware of [14, 15]. Previous tho-
racotomies may also increase the risk of significant adhe-
sions and peri-operative bleeding at later surgery or trans-
plant.  
Table 1.  Common Underlying Diagnoses by Age in Patients Requiring Heart Transplant  
Age  Diagnosis   Further Details 
< 1 month ( infancy)  Hypoplastic left heart with abnormalities precluding 
Norwood procedure  
 
Severe Ebstein’s anomaly 
 
Pulmonary atresia with intact ventricular septum 
and abnormal coronary anatomy 
 
Severe valve abnormalities 
 
 
Heterotaxy lesions 
Impaired ventricular function and inlet valve 
regurgitation 
 
Symptomatic infants 
 
Right ventricular dependent coronary circulation 
 
 
eg mitral regurgitation with impaired function. 
 
 Impaired ventricular function and inlet valve 
regurgitation 
>6 months 
 
Single ventricle 
 
 
 
 
Transposition of great arteries 
 
Right ventricular outflow tract lesions 
 
 
Ventricular/atrial septal defect 
 
 
Left ventricular outflow tract lesions 
 
Congenitally corrected-transposition of the great 
arteries 
 
 
Complete atrioventricular septal defects 
At various stages of palliation eg Blalock shunt 
(infants), Glenn shunt (young child), Fontan 
(older child) 
 
 
Typically post Mustard or Senning 
 
eg post op. repair with impairment of ventricular 
function 
 
eg post op. repair with impairment of ventricular 
function 
 
eg post op. repair with impairment of ventricular 
function 
 
eg post op. repair with impairment of ventricular 
function. Sometimes post double switch opera-
tion 
 
eg post op. repair with impairment of ventricular 
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  Prior surgical intervention indicates the potential previ-
ous exposure of the patient to blood products and human 
tissue homografts, an additional aspect of the patient’s his-
tory which must be fully evaluated prior to listing as use of 
such products increases the problem of immunological sensi-
tisation of the patient, an issue that will be discussed later. 
  Those who have undergone earlier cardiac surgery may 
also be left with atypical anatomy and communications that 
necessitate technical modification of the usual transplant 
procedure.  
EXAMINATION 
  Classically older patients with heart failure that are being 
considered for heart transplant present with symptoms of 
cardiogenic shock, shortness of breath, reduced exercise tol-
erance, anorexia and weight loss. In children signs may be 
more subtle and difficult to interpret, poor feeding, vomiting 
and lethargy not being uncommon findings within the paedi-
atric setting, but growth failure generally providing a good 
warning sign that further investigation is warranted.  
EXERCISE TESTING 
  Cardiopulmonary exercise testing is frequently used to 
evaluate patients prior to transplant. This assessment tool is 
mainly used in adult patients and some older paediatric pa-
tients, the information obtained contributing to the overall 
evaluation of the condition of the potential transplant recipi-
ent. The data obtained provides an indicator measure of mor-
bidity and mortality relative to age and sex, although 
definitive statistics are difficult to obtain regarding the im-
plication of exercise testing results as numerous exercise 
protocols exist. Oxygen consumption during a period of ex-
ercise is measured, and also commonly in the UK a six-
minute walk test is performed, but increasingly additional 
parameters are being considered as equal if not more reliable 
indices of assessment. Reduced autonomic response to exer-
cise as determined by minimal heart rate elevation in re-
sponse to an exercise challenge is associated with a higher 
risk of mortality in adult patients with congenital heart dis-
ease in general [16]. Additionally the assessment of meta-
bolic function by measurement of carbon dioxide production 
relative to ventilation is increasingly being considered as an 
additional and significant prognostic variable [17]. The use-
fulness of exercise tolerance results after cardiac surgical 
procedures is uncertain. It has been shown that after certain 
procedures such as the Fontan procedure, exercise tolerance 
may never be normal and is seen to gradually decline further, 
therefore sub-optimal results may be expected which makes 
it hard to give definitive values regarding timing of trans-
plantation. 
ECHO/ MRI 
  Echocardiogram is the most widely used imaging modal-
ity in cardiology, and it is a valuable tool in the assessment 
of potential transplant patients. Increasingly the more refined 
three dimensional imaging obtained by cardiac magnetic 
resonance imaging is being utilised to add to pre-operative 
assessment of patients. This imaging modality provides the 
clinician with invaluable additional data regarding structure, 
function, failure, tissue mass and fluid flow of the cardiovas-
cular system. The relationship of any conduits to the sternum 
and the venous connections should be determined. The pul-
monary arteries need to be carefully imaged to allow a 
planned repair of these at transplant if needed. However, it is 
well known that pulmonary artery reconstruction is an im-
portant risk factor for transplant [18].  
BNP 
  Natriuretic peptides (NP) are a group of hormones re-
sponsible for the regulation of sodium and fluid balance 
within the body. Of the three major classes of natriuretic 
peptides, A, B and C, A type natriuretic peptide (ANP) and 
B type natriuretic peptide (BNP) are released predominantly 
by the heart, their levels alter measurably in the blood in 
response to the mechanical stress placed on the myocardium.  
  BNP is a valuable prognostic marker used in the assess-
ment of heart failure. A strong association between BNP 
levels has been demonstrated with echocardiogram indices, 
clinical status and prognosis in children with left ventricular 
failure [19]. The elevated BNP identifying children at high 
risk of poor outcome in terms of prognosis and additional 
morbidity [20, 21].  
  In adults a single BNP measurement in patients with 
chronic heart failure may similarly identify those patients at 
highest risk of death, and may be a better predictive indicator 
than measurement of left ventricular ejection fraction by 
echocardiogram, peak oxygen uptake on exercise testing or 
composite scoring systems such as heart failure survival 
score [22, 23]. However, it is unclear whether BNP is useful 
in the transplant assessment of complex congenital heart 
disease. BNP appears to be of no clinical or diagnostic value 
in patients with a systemic right ventricle or Fontan circula-
tion [24] and is also not elevated in failure of cavopulmonary 
circuits with preserved ventricular function [25] but may 
vary with systemic ventricular morphology. As a result it is 
unlikely to be as useful in isolation in assessment of congeni-
tal heart disease as it appears to be in simple left ventricular 
failure, but may be helpful as part of a systematic assessment 
[26]. 
SENSITISATION  
  A matching system using human leucocyte antigens, 
those proteins on the cell surface that enable the host to dif-
ferentiate self from non-self, is used in other solid organ 
transplant protocols. The aim being to have as close a match 
in these presenting proteins as possible to reduce the likeli-
hood of transplanted organ rejection by the host. Although it 
is known that as few as three HLA mismatches may result in 
greater predisposition to rejection, unlike in other organ 
transplant programmes, full cross matching is not possible 
prior to transplant because of the limited supply of organs 
and an ischaemic time that must be kept to a minimum. A 
pre-transplant screening of the anti-HLA antibodies of poten-
tial recipients is however performed using a panel of anti-
bodies sensitised to those most common HLAs. Panel Reac-
tive Antibody (PRA) screening provides the transplant team 
with an indication of the potential immunological difficulty 
in finding a suitable donor organ, and some insight as to the 
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either empirically prepare a patient for transplant or manage 
the patient post-operatively. Patients with congenital heart 
disease are more likely than most other potential heart trans-
plant recipients to be exposed to blood products or human 
tissue during their previous management. The increasing use 
of mechanical cardiac support and left ventricular assist de-
vices, requiring frequent blood product transfusion also 
primes the recipient against HLAs. Such exposure of the 
patient to foreign HLA proteins greatly magnifies the risk of 
pre-transplant sensitisation, reducing the probability of find-
ing an immunologically good tissue match at transplant. 
Special precautions are therefore required to deal with the 
likelihood of sensitisation in this patient group. Combating 
this higher risk scenario requires directed immunotherapeutic 
strategies pre- and post transplant, with a considerable risk of 
early rejection a consequence if they are not adequately con-
trolled.  
END ORGAN DAMAGE 
  With a failing circulation cardiac output is inadequate to 
meet the requirements of other vital organs. Resultant end-
organ damage is frequently encountered and may be either 
reversible if addressed early or irreversible if refractive to 
therapy and intervention. With patients suffering with con-
genital heart disease surviving longer into adult life, addi-
tional complications and co-morbidities are being increas-
ingly observed as a result of end organ damage. The risk of 
end organ damage may be age-related, especially in patients 
with congenital heart disease as increased duration of expo-
sure to a sub-optimal circulation and the risk of additional 
organ damage is more predictable. With the limited supply 
of transplantable hearts it is vital the potential host is as-
sessed to establish the severity and reversibility of such dam-
age. Although transplant may be the only treatment modality 
to extend life in certain patients, it is inappropriate to trans-
plant a new organ into a failing body that will not be able to 
recover sufficiently its other vital functions. Even if addi-
tional organ failure is severe it may be reversible if provided 
with a restored and appropriate circulation, it is therefore the 
reversibility of the end organ damage that is most important 
for transplant teams to assess but difficult to predict.  
  All organ systems will be affected to some extent when 
in an environment of a failing circulation. Renal dysfunction 
is commonly seen as a consequence of heart failure. Ap-
proximately half the adult patients with congenital heart dis-
ease, particularly those with cyanotic conditions, have been 
observed to have significantly impaired renal function [27]. 
A three fold increase in death rate has been seen in those 
patients with moderate to severe renal failure than in patients 
with normal kidney function [27].  
  The pathophysiology of renal failure seen in patients with 
congenital heart disease is likely to be similar to that seen in 
heart failure acquired secondary to other conditions. Low 
cardiac output causing chronic renal hypoperfusion results in 
neurohormonal and autonomic upregulation measures in an 
attempt to restore an appropriate circulatory pressure. This 
unsustainable situation culminates in renal damage quantifi-
able in terms of blood analysis and GFR measurement. 
  Persistent hyponatraemia appears to be an indicator of 
outcome in patients with heart failure, independent of 
haemodynamic status [28].  
  Anaemia is seen in adults with congenital heart disease, 
and may be associated with a three- fold increase in the risk 
of death [29]. The pathophysiological process causing the 
anaemia being reduced erythropoietin production secondary 
to renal dysfunction. This is compounded by anaemia of 
chronic disease, seen as a consequence of acute or chronic 
immune activation. Although some aspects of this anaemia 
can be corrected, by administration of erythropoietin, iron 
supplementation and other measures, its presence itself indi-
cates the severity of the underlying disease process and is 
highlighted through the presenting clinical condition of the 
patient. The anaemia results in reduced oxygen carrying ca-
pacity and a transfer to anaerobic metabolism at an earlier 
stage than should be normally seen, and is recognised by a 
reduced exercise tolerance and an abnormal ventilation-
carbon dioxide production relationship on metabolic testing. 
Polycythemia is seen in severely cyanotic patients and can 
increase the risk of surgery and bleeding is more common in 
these patients post operatively. 
  Liver disease is also observed in patients with end stage 
cardiac failure, the hepatic dysfunction seen causing abnor-
mal clotting and fibrosis, later leading to cirrhosis. Liver 
status clearly being an important factor in pre-transplant as-
sessment. This is a particular problem with the failing Fontan 
circulation [30]. 
SUBJECTIVE ASSESSMENT- QUESTIONNAIRE 
  Both subjective and objective evaluation of the potential 
transplant patient is important. The use of the Minnesota 
Living with Heart Failure self assessment questionnaire is 
frequently used in adult heart failure patients. Other similar 
self- assessment surveys also exist focusing on additional 
specific aspects of heart failure, such as the London Chest 
Activities of Daily Living Scale. The wording and interpreta-
tion of the questions by patients in self evaluation does how-
ever result in variable reliability in the data that it is intended 
to assess [31]. Self estimation by patients of their physical 
functioning has been seen to relate poorly to their actual ex-
ercise capacity [32], but such questionnaires still provide 
valid information to support other more objective investiga-
tions.  
PSYCHOLOGICAL AND NEUROLOGICAL STATUS  
  The psychological stability of patients being assessed for 
transplant is also reviewed. Adults with chronic psychiatric 
illness or substance dependence may be deemed unsuitable 
for the transplant process. The wait for transplant once listed 
is also an extremely difficult time for all patients and their 
families so ongoing support and assessment should be main-
tained. Poor quality of life and inability to participate in the 
normal routines and activities of daily living affect the emo-
tional well being of children and adults alike. Patients with 
congenital heart disease frequently only rate their physical 
functioning and general health during assessment, rarely 
ranking psychosocial aspects of their illness, despite obser-
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more significant impact on their quality of life than exercise 
capacity [32, 33]. 
  The neurological status and development of patients with 
congenital heart disease is also pertinent. Neurological com-
plications of uncorrected congenital disorders include stroke 
and brain abscess, as well as the adverse influence on neuro-
development. In addition there are complications that arise as 
a consequence of cardiac surgery especially in the young, the 
neurological complications of cardiac bypass and hypother-
mic circulatory arrest being well documented [34].  
MECHANICAL SUPPORT 
  When the cardiac status fails completely and mechanical 
support is required to preserve life, the risk of additional 
complications is magnified both through the severity of the 
presenting heart failure and the risks associated with its man-
agement.  
  Extra-corporeal membrane oxygenation (ECMO) may be 
more rapidly utilised than left ventricular assist devices and 
may provide short term support in emergency situations, but 
carries considerable procedural and consequent risk. It has 
been more commonly used in paediatrics than in adults. It is 
clear that ECMO significantly increases the risk of heart 
transplantation. Left ventricular assist devices however offer 
the patient the advantages of long term cardiac support with-
out the need for continuous sedation or respiratory support, 
indeed many patients live relatively normal lives with an 
LVAD inserted whilst waiting the increasingly long periods 
for a transplant. Studies have concluded that children requir-
ing LVAD support prior to heart transplant have the same 
survival outcomes as those who do not [35].  
  However, there is very little in the literature on VAD 
support for failing congenital heart disease. It is clearly diffi-
cult to balance pulmonary and systemic flow in the failing 
single ventricle and may be very difficult in the failing Fon-
tan circulation. There are some successful case reports, but 
the wider US experience with the Berlin Heart which will be 
published in the near future will give a much clearer idea 
about the risk of support in complex congenital heart disease.  
  The need for ventilator support prior to cardiac transplant 
also confers poorer prognostic outcome.  
OUTCOME OF ASSESSMENT 
  Rigorous assessment by the multi-disciplinary team en-
ables the most appropriate candidates to be selected for heart 
transplantation. Patients may be categorised on the results of 
the described investigations as being either high or low risk 
for the procedure and are also classified as either urgent or 
standard depending on their prevailing clinical condition. 
Some patients with congenital cardiac defects who do sur-
vive childhood and progress to adult cardiac services may 
not however get listed due to the consequent high risk pres-
entation of end organ damage, raised PVR, previous thoraco-
tomies and associated adhesions, chronic formation of col-
lateral circulations and immune sensitisation.  
  Due to the shortage of donor organs priority is generally 
given to the sickest patients, with those individuals listed as 
urgently needing a new organ being considered before others 
that are more stable when an organ becomes available. The 
psychological strain on the individual and the family in-
volved whilst waiting for an indeterminate duration on a 
transplant waiting list is hard to comprehend The clinical 
status of the patient may fluctuate during this time and due to 
the supply and demand inequality of the transplant pro-
gramme, patients die whilst waiting for a new heart. In the 
United States of all the children listed for heart transplanta-
tion between 1999 and 2006 17% died before an organ be-
came available for them [36].  
ENVIRONMENT NEEDED TO PROVIDE A RELI-
ABLE SERVICE 
  To optimise the effectiveness of a cardiac transplantation 
programme for patients with congenital heart disease facili-
ties and skills need to be appropriate for the difficulties that 
may be encountered. The available surgeons and transplant 
team including nurses, anaesthetists, perfusionists, cardiolo-
gists and intensivists need to be skilled in the field of con-
genital cardiac surgery themselves, so that atypical anatomy, 
previous reparative surgical techniques and potential hazards 
may be appreciated and anticipated. Donor organs for pa-
tients with congenital defects often require extended struc-
tures to remain intact at explantation to permit effective 
transplantation into the recipient with structurally abnormal 
anatomy. Extended harvest of systemic and pulmonary vas-
culature may assist with the implantation into the recipient 
but may limit the use of other potential donor organs, par-
ticularly the lungs. Consideration needs also to be paid to 
managing the medical risk factors and complications high-
lighted such as renal dysfunction, clotting aberrations, ele-
vated PVR and sensitisation.  
POSSIBLE SOLUTIONS 
  At a critical time for the heart transplant service, as donor 
organs are in such low supply, but demands in all age groups 
remain high, serious thought must be given as to how we 
may redress the balance. More rigorous assessment criteria 
could be imposed restricting the use of the limited organs 
offered to those with the best potential outcome, but this 
would limit the service by exclusion of whole patient popula-
tions, including those with congenital lesions. But not all 
congenital heart disease is the same. For example transplant 
following the Senning and Mustard procedures is possible 
with low risk, while transplant for the failing Fontan patients 
has an 8.6 times increased relative risk of death [37]. Careful 
consideration of multiple risk factors can give an estimate of 
the potential morbidity and mortality of cardiac transplant in 
an individual, some patients may be considered so high risk 
that transplant is not a viable option. For example a recent 
post sternotomy Fontan patient on ECMO, with impaired 
renal function, probable high PVR, protein losing enteropa-
thy and high immunological sensitization would be a very 
high risk case, whereas an ambulatory, non-sensitised Sen-
ning patient with systemic ventricular failure would be a low 
risk case.  Exactly where to draw the line between these two 
extremes has not been defined, yet as organ availability de-
clines transplant physicians will have to make very difficult 
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  With the advantages of heart transplant in infancy ob-
served, perhaps more transplants should be aimed at this age 
group, even if organs are not best matched immunologically 
and may even be marginal in other characteristrics such as 
size, good outcomes are still observed. Heart transplantation 
in infancy may be advantageous in many ways but may also 
enforce the life- limiting implications of transplant onto the 
extremely young before the natural course of the disorder 
can be fully determined. Ethical debate persists as to how 
donors may be most appropriately selected and creates an-
other topic for crucial negotiation [38].  
  As heart failure management progresses, particularly 
with the increasing use of mechanical support in all age 
groups, perhaps clinicians will be focusing on alternative and 
novel treatment modalities to reduce the need of transplant, 
especially for conditions where a structurally normal heart 
exists, but where dysfunction has occurred via disease proc-
esses such as muscle damage. Reducing the demand for or-
gans by medical or surgical means would begin to modify 
such an unbalanced situation. 
SUMMARY 
  The field of cardiac transplantation is clearly complicated 
with additional early risk factors for morbidity and mortality 
attached than are encountered in many other transplant situa-
tions, but with careful planning these may be addressed and 
minimised. If patients survive the early operative complica-
tions of their transplant, late survival rates appear to be com-
parable to survival of transplant for other cardiac indications 
such as cardiomyopathy [39]. This trend is seen in both 
adults and children requiring transplant for congenital heart 
disease [39, 40].  
  Many factors contribute to the decision to transplant pa-
tients with congenital heart disease. Consideration should be 
paid to the optimal timing of referral to a transplant team for 
assessment. Assessment of paediatric and adult patients var-
ies considerably in ease of assessment and reliability of re-
sults. Certain clinical presentations and underlying diagnoses 
as well as co-morbidities are recognised as stratifying pa-
tients to high risk and low risk categories for outcome of 
transplant, indeed certain pathologies are deemed to be con-
traindications to transplant. The ISHLT has brought together 
experts in the field of heart transplantation from around the 
world to develop consensus guidelines for the management 
of transplantation. Their guidelines offer advice regarding 
suitability of donor organs and peri-and post operative man-
agement.  
Appendix A: Contraindications to Heart Transplantation ( Data taken from UK Transplant National Protocol for Assessment of 
Cardiothoracic Transplant patients, published March 2002, reviewed February 2005, prepared by the UKT Cardiothoracic Advi-
sory Group): 
Absolute Contraindications to Heart Transplantation:  Relative Contraindications to Heart Transplantation: 
 Chronic current systemic infection, including endocarditis 
 
 Chronic extracardiac infection 
 
 Active peptic ulcer 
 
 Continued abuse of alcohol or other drugs 
 
 Irreversible secondary organ failure unless considering for combined 
transplant 
 
 Psychiatric history likely to result in non-compliance and/ or persis-
tent non-compliance with medical therapy 
 
 Severe peripheral or cerebrovascular disease 
 
 Malignancy 
 
 Other life-threatening medical condition, likely to cause death within 
five years 
 HIV ( subject to discussion with Medical Director at UK Transplant) 
 
 Hepatitis B/C 
 
 Acute pulmonary embolus ( within 3 months) 
 
 Obesity BMI>30 
 
 COPD with FEV1<50% predicted 
 
 Pulmonary vascular resistance greater than 4 Woods Units 
 
 Transpulmonary gradient greater than 12mmHg 
 
 Chronic renal impairment with GFR<50ml/min, unless candidate for com-
bined renal transplant 
 
 Diabetes with target organ damage 
 Hypercholesterolaemia or other lipid diseases refractory to diet or drug ther-
apy 
 Severe osteoporosis (bone mineral density > 2sd’s less than predicted for age) 
 Amyloidosis 
 Continued smoking 
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  With increasingly short supplies of organs available for 
transplantation, and those being donated often crossing in-
ternational boundaries, it is more important than ever that 
transplant teams, clinicians and co-ordinators maintain 
communication to produce and update structured guidelines 
and international standards on which informed and rational 
decisions can be made as to how these organs can be most 
effectively utilised. The complex and continually evolving 
field of transplantation, particularly for congenital heart dis-
ease, deserves international collaboration via consultation 
and database registries to permit effective management of 
the individual patient. Difficulty arises however when at-
tempting to provide a unified management strategy when 
clearly the field of congenital heart disease is such a hetero-
geneous topic, with variability in risk factors, co-morbidities 
and outcomes [13] yet it is incumbent on transplant teams to 
begin to address this difficult subject. 
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